Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Lip Gregory Y H) "

Sökning: WFRF:(Lip Gregory Y H)

  • Resultat 1-10 av 85
  • [1]234567...9Nästa
Sortera/gruppera träfflistan
  • Kotecha, Dipak, et al. (författare)
  • Integrating new approaches to atrial fibrillation management : the 6th AFNET/EHRA Consensus Conference.
  • 2018
  • Ingår i: Europace. - 1099-5129 .- 1532-2092. ; 20:3, s. 395-407
  • Tidskriftsartikel (refereegranskat)abstract
    • There are major challenges ahead for clinicians treating patients with atrial fibrillation (AF). The population with AF is expected to expand considerably and yet, apart from anticoagulation, therapies used in AF have not been shown to consistently impact on mortality or reduce adverse cardiovascular events. New approaches to AF management, including the use of novel technologies and structured, integrated care, have the potential to enhance clinical phenotyping or result in better treatment selection and stratified therapy. Here, we report the outcomes of the 6th Consensus Conference of the Atrial Fibrillation Network (AFNET) and the European Heart Rhythm Association (EHRA), held at the European Society of Cardiology Heart House in Sophia Antipolis, France, 17-19 January 2017. Sixty-two global specialists in AF and 13 industry partners met to develop innovative solutions based on new approaches to screening and diagnosis, enhancing integration of AF care, developing clinical pathways for treating complex patients, improving stroke prevention strategies, and better patient selection for heart rate and rhythm control. Ultimately, these approaches can lead to better outcomes for patients with AF.
  • Wieloch, Mattias, et al. (författare)
  • Estimated glomerular filtration rate is associated with major bleeding complications but not thromboembolic events, in anticoagulated patients taking warfarin.
  • 2013
  • Ingår i: Thrombosis Research. - : Elsevier Ltd. - 1879-2472 .- 0049-3848. ; 131:6, s. 481-486
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Decreased glomerular filtration rate is an established risk factor for bleeding but there are limited data on its association with bleeding risk in well-controlled anticoagulated patients taking warfarin. OBJECTIVES: The aim was to investigate the relationship between glomerular filtration rate, major bleeding and thromboembolic complications in patients with tight anticoagulation control. PATIENTS/METHODS: A cohort study of patients from a Swedish quality register for anticoagulation, including all the registered patients that received anticoagulation during 2008 in the anticoagulation center of Skåne University Hospital, Malmö. Key outcome measures were major bleeding and arterial or venous thrombosis during 2008. A total of 3536 patients (2875 treatment years) were included. RESULTS: Total rates of 2.6 (2.0-3.2) bleeding events and 1.8 (1.3-2.3) thrombotic events per 100 treatment years were recorded (75 bleeding and 51 thromboembolic events). Data on estimated glomerular filtration rate were available in 3349 patients. Mean time in therapeutic range (international normalized ratio 2.0-3.0) was 74.5% (n=2894). Major bleeding events were significantly related to age and percentage of time with international normalized ratio >3.0 (P<0.001). Glomerular filtration rate levels <30ml/min/1.73m(2) were particularly associated with high risk of bleeding, especially in elderly patients. No correlation between glomerular filtration rate and thromboembolic events was seen. CONCLUSIONS: With good anticoagulation control as measured by time in therapeutic range, patients had a relatively low risk for major bleeding if their renal function is normal. Despite good anticoagulation control, severely impaired kidney function is associated with a very high yearly risk of major bleeding events.
  • Freedman, Ben, et al. (författare)
  • Screening for Atrial Fibrillation A Report of the AF-SCREEN International Collaboration
  • 2017
  • Ingår i: Circulation. - : LIPPINCOTT WILLIAMS & WILKINS. - 0009-7322 .- 1524-4539. ; 135:19, s. 1851-
  • Tidskriftsartikel (refereegranskat)abstract
    • Approximately 10% of ischemic strokes are associated with atrial fibrillation (AF) first diagnosed at the time of stroke. Detecting asymptomatic AF would provide an opportunity to prevent these strokes by instituting appropriate anticoagulation. The AF-SCREEN international collaboration was formed in September 2015 to promote discussion and research about AF screening as a strategy to reduce stroke and death and to provide advocacy for implementation of country-specific AF screening programs. During 2016, 60 expert members of AF-SCREEN, including physicians, nurses, allied health professionals, health economists, and patient advocates, were invited to prepare sections of a draft document. In August 2016, 51 members met in Rome to discuss the draft document and consider the key points arising from it using a Delphi process. These key points emphasize that screen-detected AF found at a single timepoint or by intermittent ECG recordings over 2 weeks is not a benign condition and, with additional stroke factors, carries sufficient risk of stroke to justify consideration of anticoagulation. With regard to the methods of mass screening, handheld ECG devices have the advantage of providing a verifiable ECG trace that guidelines require for AF diagnosis and would therefore be preferred as screening tools. Certain patient groups, such as those with recent embolic stroke of uncertain source (ESUS), require more intensive monitoring for AF. Settings for screening include various venues in both the community and the clinic, but they must be linked to a pathway for appropriate diagnosis and management for screening to be effective. It is recognized that health resources vary widely between countries and health systems, so the setting for AF screening should be both country-and health system-specific. Based on current knowledge, this white paper provides a strong case for AF screening now while recognizing that large randomized outcomes studies would be helpful to strengthen the evidence base.
  • Kirchhof, Paulus, et al. (författare)
  • Comprehensive risk reduction in patients with atrial fibrillation : emerging diagnostic and therapeutic options - a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference
  • 2012
  • Ingår i: Europace. - 1099-5129 .- 1532-2092. ; 14:1, s. 8-27
  • Forskningsöversikt (refereegranskat)abstract
    • While management of atrial fibrillation (AF) patients is improved by guideline-conform application of anticoagulant therapy, rate control, rhythm control, and therapy of accompanying heart disease, the morbidity and mortality associated with AF remain unacceptably high. This paper describes the proceedings of the 3rd Atrial Fibrillation NETwork (AFNET)/European Heart Rhythm Association (EHRA) consensus conference that convened over 60 scientists and representatives from industry to jointly discuss emerging therapeutic and diagnostic improvements to achieve better management of AF patients. The paper covers four chapters: (i) risk factors and risk markers for AF; (ii) pathophysiological classification of AF; (iii) relevance of monitored AF duration for AF-related outcomes; and (iv) perspectives and needs for implementing better antithrombotic therapy. Relevant published literature for each section is covered, and suggestions for the improvement of management in each area are put forward. Combined, the propositions formulate a perspective to implement comprehensive management in AF.
  • Bjorck, Fredrik, et al. (författare)
  • Outcomes in a Warfarin-Treated Population With Atrial Fibrillation
  • 2016
  • Ingår i: JAMA cardiology. - : American Medical Association. - 2380-6583 .- 2380-6591. ; 1:2, s. 172-180
  • Tidskriftsartikel (refereegranskat)abstract
    • IMPORTANCE Vitamin K antagonist (eg, warfarin) use is nowadays challenged by the non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation (AF). NOAC studies were based on comparisons with warfarin arms with times in therapeutic range (TTRs) of 55.2% to 64.9%, making the results less credible in health care systems with higher TTRs. OBJECTIVES To evaluate the efficacy and safety of well-managed warfarin therapy in patients with nonvalvular AF, the risk of complications, especially intracranial bleeding, in patients with concomitant use of aspirin, and the impact of international normalized ratio (INR) control. DESIGN, SETTING, AND PARTICIPANTS A retrospective, multicenter cohort study based on Swedish registries, especially AuriculA, a quality register for AF and oral anticoagulation, was conducted. The register contains nationwide data, including that from specialized anticoagulation clinics and primary health care centers. A total of 40 449 patients starting warfarin therapy owing to nonvalvular AF during the study period were monitored until treatment cessation, death, or the end of the study. The study was conducted from January 1, 2006, to December 31, 2011, and data were analyzed between February 1 and November 15, 2015. Associating complications with risk factors and individual INR control, we evaluated the efficacy and safety of warfarin treatment in patients with concomitant aspirin therapy and those with no additional antiplatelet medications. EXPOSURES Use of warfarin with and without concomitant therapy with aspirin. MAIN OUTCOMES AND MEASURES Annual incidence of complications in association with individual TTR (iTTR), INR variability, and aspirin use and identification of factors indicating the probability of intracranial bleeding. RESULTS Of the 40 449 patients included in the study, 16 201 (40.0%) were women; mean (SD) age of the cohort was 72.5 (10.1) years, and the mean CHA(2)DS(2)-VASc (cardiac failure or dysfunction, hypertension, age >= 75 years [doubled], diabetes mellitus, stroke [doubled]-vascular disease, age 65-74 years, and sex category [female]) score was 3.3 at baseline. The annual incidence, reported as percentage (95% CI) of all-cause mortality was 2.19% (2.07-2.31) and, for intracranial bleeding, 0.44%(0.39-0.49). Patients receiving concomitant aspirin had annual rates of any major bleeding of 3.07%(2.70-3.44) and thromboembolism of 4.90% (4.43-5.37), and those with renal failure were at higher risk of intracranial bleeding (hazard ratio, 2.25; 95% CI, 1.32-3.82). Annual rates of any major bleeding and any thromboembolism in iTTR less than 70% were 3.81% (3.51-4.11) and 4.41% (4.09-4.73), respectively, and, in high INR variability, were 3.04%(2.85-3.24) and 3.48% (3.27-3.69), respectively. For patients with iTTR 70% or greater, the level of INR variability did not alter event rates. CONCLUSIONS AND RELEVANCE Well-managed warfarin therapy is associated with a low risk of complications and is still a valid alternative for prophylaxis of AF-associated stroke. Therapy should be closely monitored for patients with renal failure, concomitant aspirin use, and poor INR control.
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 85
  • [1]234567...9Nästa
Typ av publikation
tidskriftsartikel (75)
forskningsöversikt (9)
konferensbidrag (1)
Typ av innehåll
refereegranskat (81)
övrigt vetenskapligt (4)
Lip, Gregory Y H (88)
Blomström-Lundqvist, ... (38)
Kirchhof, Paulus (17)
Boriani, Giuseppe (17)
Hohnloser, Stefan H (16)
De Caterina, Raffael ... (13)
visa fler...
Cannon, Christopher ... (13)
ten Berg, Jurrien M. (13)
Bhatt, Deepak L. (12)
Oldgren, Jonas, 1964 ... (12)
Dagres, Nikolaos (12)
Camm, A. John (12)
Huber, Kurt (10)
Auricchio, Angelo (10)
Nordaby, Matias (10)
Kimura, Takeshi (10)
Gorenek, Bulent (10)
Hindricks, Gerhard (9)
Steg, Philippe Gabri ... (9)
Potpara, Tatjana S (9)
Andreotti, Felicita (9)
Goette, Andreas (9)
Sechtem, Udo (9)
Dean, Veronica (8)
Filippatos, Gerasimo ... (8)
Olsson, Bertil (8)
Fauchier, Laurent (8)
Vahanian, Alec (8)
Kristensen, Steen Da ... (8)
Lewalter, Thorsten (8)
Funck-Brentano, Chri ... (8)
Schotten, Ulrich (8)
Tendera, Michal (7)
Morais, Joao (7)
Mont, Lluis (7)
Calkins, Hugh (7)
Kuck, Karl-Heinz (7)
Brueckmann, Martina (7)
Svendsen, Jesper Has ... (7)
Camm, John (7)
Siegbahn, Agneta (6)
Husted, Steen (6)
Verheugt, Freek W. A ... (6)
Dickstein, Kenneth (6)
Brandes, Axel (6)
Heidbuchel, Hein (6)
Pison, Laurent (6)
Potpara, Tatjana (6)
Popescu, Bogdan A (6)
Rutten, Frans H (6)
visa färre...
Uppsala universitet (73)
Lunds universitet (11)
Linköpings universitet (5)
Umeå universitet (3)
Karolinska Institutet (3)
Göteborgs universitet (2)
Engelska (83)
Italienska (1)
Polska (1)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (51)


pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy